AI Article Synopsis
- Tumour development can trigger a systemic immune response aimed at protecting the host, but it can also cause partial immunodeficiency, allowing tumours to evade a full immune attack.
- Since the 1960s, especially after Bloom's studies, various medical fields have explored using the immune system to fight different types of cancer, including high-grade gliomas.
- This study focuses on how the immune response works in the Central Nervous System, the tactics astrocytic tumours use to escape immune detection, and reviews existing research on immunotherapy's mechanisms and clinical outcomes.
Article Abstract
It is generally accepted that tumour development promotes a systemic response leading to protect the host against cancer. However, tumours may as well elicit a partial immunodeficiency to avoid the development of a complete and active immune response. Since Bloom's first studies on immunotherapy to treat high grade gliomas in 1960, many attempts have been made from different medical specialties to use the immune system as a weapon against a great diversity of cancers. Main objective of this study is to outline the basic features of the immune response inside the Central Nervous System, the strategies employed by astrocytic tumours to evade body defences, and to provide an extended literature review on research on immunotherapy, especially concerning its patho-physiology and the clinical results achieved till date.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!